Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProvONE: Sipuleucel-T Booster in mCRPC
NCT06134232Phase 2Recruiting
- Sponsor
- Dendreon
- Start
- Oct 2023
- Primary completion
- Dec 2031
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dendreon. Started Oct 2023; status: recruiting.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06134232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134232.